Cancer prognosis is predicted with respect to the primary tumor size, extent of tumor invasion, spread to lymph nodes and distant organs, and levels of biomarkers. Various biomarkers have been developed to predict head and neck squamous cell carcinoma (HNSCC) prognosis . Using tumor tissue specimens or blood samples, these biomarkers are measured. However, tissue biomarkers that are measured using a biopsy specimen do not always reflect the nature of the whole tumor. Furthermore, tissue biomarker studies frequently demonstrate contradictory results because of variations in tissue processing (fresh or fixed) and scoring procedures . Obtaining specimens through invasive procedures sometimes limit the availability. On the other hand, blood biomarkers are easily obtained through non-invasiveness procedures. Leukocyte count, serum inflammatory marker levels, and serum SCC antigen levels are reliable prognostic markers for HNSCC [2–4]. However, these prognostic blood biomarkers rarely provide additional prognostic information regarding the TNM staging. Therefore, despite having prognostic abilities, these biomarkers are not clinically useful.